Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7058 + SHR-A2102 + SHR-1316 + BP102
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
HRS-7058 + SHR-A2102 + SHR-1316 + BP102 is a four-drug combination therapy being developed by Shandong Suncadia Medicine (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for the treatment of advanced malignant solid tumors. The regimen consists of HRS-7058, an ERK1/2 inhibitor; SHR-A2102, an antibody-drug conjugate (ADC) targeting Nectin-4; SHR-1316 (adebrelimab), a monoclonal antibody targeting programmed death-ligand 1 (PD-L1); and BP102, a biosimilar of bevacizumab targeting vascular endothelial growth factor (VEGF). This combination aims to simultaneously inhibit the MAPK/ERK signaling pathway, deliver cytotoxic payloads to Nectin-4 expressing cells, enhance anti-tumor immune responses via checkpoint inhibition, and inhibit angiogenesis. It is currently being evaluated in Phase II clinical trials.
- Other names
- HRS-7058 + SHR-A2102 + SHR-1316 + BP102
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on HRS-7058 + SHR-A2102 + SHR-1316 + BP102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7058 + SHR-A2102 + SHR-1316 + BP102.